insights_auto
Why is HELP up ၁၀.၀၇%?
Dive Deeperchevron_right
HELP:NASDAQ
Cybin Inc
၁၁.၈၀ US$
arrow_upward
+၁၀.၀၇%(+၁.၀၈) 1D
၁၁.၉၅ US$
arrow_upward
+၁.၂၇% (+၀.၁၅)bedtimeAfter hours
Closed: အောက် ၉, GMT-၄ ၁၆:၀၀:၀၁ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HELP...
Open
၁၀.၇၅ US$
High
၁၂.၀၉ US$
Low
၁၀.၄၅ US$
Avg. vol.
၁.၅၉ သန်း
Volume
၁.၆၆ သန်း
52-wk high
၁၅.၁၅ US$
52-wk low
၃.၇၆ US$
Beta
၀.၅၃
Shares outstanding
၇.၃၁ ကုဋေ
No. of employees
၁၀၀
Open
၁၀.၇၅ US$
High
၁၂.၀၉ US$
Low
၁၀.၄၅ US$
Avg. vol.
၁.၅၉ သန်း
Volume
၁.၆၆ သန်း
52-wk high
၁၅.၁၅ US$
52-wk low
၃.၇၆ US$
Beta
၀.၅၃
Shares outstanding
၇.၃၁ ကုဋေ
No. of employees
၁၀၀
News stories
From web sources and news partners
Seeking Alpha
·
ပြီးခဲ့သည့် ၇ နာရီ
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout (NASDAQ:HELP)
TipRanks
·
ပြီးခဲ့သည့် ၃ ရက်
Helus Pharma Sets Investor Presentation to Spotlight Late-Stage Mental Health Pipeline
Investing.com
·
ပြီးခဲ့သည့် ၃ ရက်
H.C. Wainwright reiterates Helus Pharma stock rating at buy
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Cybin Inc
CEO-
Employees၁၀၀
Founded၂၀၁၉
Headquartersတိုရွန်တိုမြို့, အွန်တေးရီးယိုးပြည်နယ်, ကနေဒါ
Sector-
Websitehelus.com